Description

IBS symptom severity scores are compared between Bacillus coagulans and placebo groups over the 80-day treatment period, showing improvements in abdominal pain, bloating, and stool consistency.

Figure 2

Chart

Source Paper

Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel …

Scientific reports (2019)

PMID: 31434935

DOI: 10.1038/s41598-019-48554-x

Cite This Figure

![Figure 2: IBS symptom severity scores are compared between Bacillus coagulans and placebo groups over the 80-day treatment period, showing improvements in abdominal pain, bloating, and stool consistency.]()

> Source: Ratna Sudha Madempudi et al. "Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2." *Scientific reports*, 2019. PMID: [31434935](https://pubmed.ncbi.nlm.nih.gov/31434935/)

<figure>
  <img src="" alt="IBS symptom severity scores are compared between Bacillus coagulans and placebo groups over the 80-day treatment period, showing improvements in abdominal pain, bloating, and stool consistency." />
  <figcaption>Figure 2. IBS symptom severity scores are compared between Bacillus coagulans and placebo groups over the 80-day treatment period, showing improvements in abdominal pain, bloating, and stool consistency.<br>  Source: Ratna Sudha Madempudi et al. "Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2." <em>Scientific reports</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31434935/">31434935</a></figcaption>
</figure>

Preuves associées

Bacillus coagulans pour Irritable Bowel Syndrome (IBS)

Note B · 3 études